Chronic Obstructive Pulmonary Disease (COPD) is a long‑term lung condition that makes breathing difficult because the airways become narrowed and the lungs lose elasticity. People with moderate‑to‑severe COPD often experience shortness of breath, coughing, and reduced ability to do everyday activities. The study tests an investigational drug called Brenipatide, identified by the code LY3537031, which is given as a small injection under the skin (subcutaneous use). A matching placebo that looks the same but contains no active medication is also used for comparison.
The purpose of the study is to determine whether Brenipatide can improve lung function compared with placebo in adults with COPD. Lung function is mainly assessed by measuring the change from the start of the trial in the amount of air a person can force out of the lungs in one second, known as Forced Expiratory Volume in 1 Second (FEV1). This measurement helps to understand how well the lungs are working.
Participants will be randomly assigned to receive either the study drug or placebo for approximately one year, with regular clinic visits to receive the injection, monitor health, and check for any side effects. Throughout the study, safety checks and simple breathing tests will be performed to gather information on how the treatment affects the disease.
Czechia 
Denmark 
France 
Germany 
Hungary 
Poland 